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Immune cell characteristics and 
cytokine responses in adult HIV-
negative tuberculous meningitis: 
an observational cohort study
Arjan van Laarhoven  1,2, Sofiati Dian1,2,3, Suzanne van Dorp2,4, Feby purnama2, 
Valerie A. C. M. Koeken  1,2, Emira Diandini2, Fitria Utami2, Resvi Livia2, Lika Apriani2, 
edwin Ardiansyah1,2, Rob ter Horst1, Mihai G. Netea  1,5, Tri Hanggono Achmad6, 
philip C. Hill7, Rovina Ruslami8, Bachti Alisjahbana2, James E. Ussher  9, Agnes Indrati2, 
Ayesha Verrall  9, Ahmad Rizal Ganiem2,3 & Reinout van Crevel1
Immunopathology contributes to high mortality in tuberculous meningitis (TBM) but little is known 
about the blood and cerebrospinal fluid (CSF) immune response. We prospectively characterised the 
immune response of 160 TBM suspects in an Indonesian cohort, including 67 HIV-negative probable 
or definite TBM cases. TBM patients presented with severe disease and 38% died in 6 months. Blood 
from TBM patients analysed by flow cytometry showed lower αβt and γδT cells, NK cells and MAIT 
cells compared to 26 pulmonary tuberculosis patients (2.4-4-fold, all p < 0.05) and 27 healthy controls 
(2.7-7.6-fold, p < 0.001), but higher neutrophils and classical monocytes (2.3-3.0-fold, p < 0.001). CSF 
leukocyte activation was higher than in blood (1.8-9-fold). CSF of TBM patients showed a predominance 
of αβT and NK cells, associated with better survival. Cytokine production after ex-vivo stimulation of 
whole blood showed a much broader range in TBM compared to both control groups (p < 0.001). Among 
TBM patients, high ex-vivo production of TNF-α, IL-6 and IL-10 correlated with fever, lymphocyte count 
and monocyte HLA-DR expression (all p < 0.05). TBM patients show a strong myeloid blood response, 
with a broad variation in immune function. This may influence the response to adjuvant treatment and 
should be considered in future trials of host-directed therapy.
Meningitis is the most severe manifestation of tuberculosis, leaving 30–50% of patients deceased or disa-
bled. Immune pathology is thought to play an important role in the poor outcome of tuberculous meningi-
tis (TBM)1. Adjuvant corticosteroids have shown an overall beneficial effect on survival in HIV-uninfected 
patients, especially in those with milder disease2 and are therefore part of routine care. It is conceivable, however, 
that a hypo-inflammatory subgroup of patients3 would benefit from withholding corticosteroids as currently 
examined in HIV-negative patients (NCT02588196), while hyper-inflammatory patients may need additional 
anti-inflammatory treatment4. More detailed information on the local and systemic immune response is needed 
to rationally select adjuvant agents and patient subgroups for improving host-direct therapy for TBM.
Routine cerebrospinal fluid (CSF) assessment only distinguishes mononuclear from polymorphonuclear cells. 
The latter, mostly neutrophils, make up on average one third of CSF cells, with higher proportions associated 
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with a worse prognosis5. Microscopic study of CSF mononuclear cells has shown wide variability of cell types and 
counts6. Analysis by flow cytometry has confirmed the presence of αβT and γδT cells, B cells and Natural Killer 
(NK) cells in CSF of TBM patients7,8, but these cells have not yet been quantified. NK cells can kill extracellular 
M. tuberculosis and trigger effector mechanisms in macrophages9. Other innate lymphocyte populations might 
also be of importance. Mucosal associated invariant T (MAIT) cells recognize M. tuberculosis and are found in 
the lung in pulmonary tuberculosis10. NKT cell number and function are reduced in the blood of tuberculosis 
patients11. Monocytes (myeloid mononuclear cells) recognise M. tuberculosis, steer immunity and mature into 
macrophages with killing capacity12. Only one study has examined ex-vivo monocyte responsiveness in TBM8.
In this study we first characterised and quantified leukocytes in a prospective cohort of TBM patients in blood 
and CSF. We then established immune phenotype based on ex-vivo whole blood cytokine assays, using pulmonary 
tuberculosis patients and healthy controls for comparison. We investigated whether separate ‘high-responding’ 
and a ‘low-responding’ immune phenotypes exist and possibly correlate with disease phenotype and outcome.
Methods
setting and patients. We prospectively included all patients >14 years of age who presented with sus-
pected tuberculous meningitis (TBM; subacute illness including headache, fever or focal neurological symp-
toms) between December 2014 and July 2016 in the Hasan Sadikin hospital in Bandung, Indonesia. This is a 
tertiary referral hospital with 966 beds, serving the population of West-Java (43 million). Standardized screening 
and diagnosis as ‘definite TBM’ (CSF culture or Gene Xpert positive) or ‘probable TBM’ (CSF to blood glu-
cose ratio was <0.5 combined with a CSF cell count ≥5 cells/μL), followed the protocols previously established 
in this setting5. Follow-up samples (day 2 and 10 for CSF and day 10, 60 and 180 for blood) were done for a 
subset of patients included in a clinical trial on high-dose rifampicin with inclusion up until November 2016 
(NCT02169882). After hospital discharge, patients were followed-up clinically at day 90 and 180. Patients not 
returning to the hospital were phoned by a social worker. Cause of death, obtained from hospital records or ver-
bal autopsy for those who died after discharge, was classified as: primarily TBM-related (i.e. brain herniation or 
otherwise increased intracranial pressure); pneumonia or sepsis; other, including non-infection related causes, 
such as injury, pulmonary embolism and aspiration pneumonia.
Pulmonary tuberculosis patients from the same hospital had chest X-ray abnormalities consistent with pul-
monary tuberculosis and 25/26 patients were confirmed by positive sputum culture or smear. Asymptomatic 
pulmonary tuberculosis household contacts linked to the same study, who had no tuberculosis-suggestive symp-
toms or X-ray abnormalities and who were Interferon-γ Release Assay (IGRA)-negative were used as controls. 
HIV-infected patients or controls were excluded from final analysis.
ethics statement. Samples for this study were collected as part of three ongoing studies approved by 
the Ethical Committee of Hasan Sadikin Hospital/Faculty of Medicine of Universitas Padjadjaran, Bandung, 
Indonesia. TBM patients were included under the project “Optimization of Diagnosis of Meningitis”. This study 
sampled only at regular venepunctures and lumbar punctures moments that are part of routine care, for which 
patients gave consent orally. Consent was given by close relatives of patients who were unconscious. Consent 
was registered in a REDCap13 clinical research form for all patients. Of note, the same procedure was followed 
for patients over 14 and under 18 years of age, who are considered adult according to local custom. This study 
procedure received ethical clearance by the institutional review board of the Hasan Sadikin Hospital (Registration 
Number 449/UN6.C1.3.3/KEPK/PN/2015). TBM patients who were part of the high-dose rifampicin study 
(NCT02169882) gave separate written consent for that study (299/UN6.C2.1.2/KEPK/PN/2014). Pulmonary TB 
patients were part of the TANDEM study14 (42/UN6.C1.3.2/KEPK/PN/2015) and healthy controls were part of 
the INFECT study (14/UN6.C2.1.2/KEPK/PN/2014). Pulmonary TB patients and healthy controls gave written 
consent for sampling. All samples were handled anonymized.
Flow cytometry. CSF was spun slowly (300 × g) for 3 minutes to avoid cell activation, the sediment was 
resuspended immediately (median 0.8 hours, IQR 0.7–1.0) in 2.5 mL RPMI (ThermoFisher, 22409031) and stored 
at 4 °C prior to flow cytometry (median 8.7 hours, IQR 4.0–16.2) later. Cell fixation interferes with measure-
ment of activation markers and was therefore not performed. Blood was collected in lithium-heparin tubes and 
stored at 20–23 °C. Blood and CSF samples were processed within 24 hours of collection. Samples were divided in 
four equal parts, to which a fixed amount (5 μL for CSF, 30 μL for blood) of microparticles (Invitrogen 123count 
eBeads, 01–1234) was added for quantification, together with fluorochrome-labeled antibodies in four panels: A 
monocyte/neutrophil panel: CD14 (AF488), CD16 (PE), HLA-DR (PerCP) and CXCR4 (APC); a NK cell panel: 
CD3 (AF488), CD16 (PE), CD56 (PerCP) and CD69 (APC); a γδT/NKT cell panel: CD3 (AF488), Vα24-Jα18 
(PE), Vδ2 (PerCP) and γδ-TCR (APC) and a MAIT cell panel: CD3 (AF488), Vα7.2 (PE), HLA-DR (PerCP) 
and CD161 (APC). Data were acquired till 1,000,000 events (blood) or a maximum of two minutes (CSF), and 
were analysed using Kaluza 1.3 (Beckman Coulter) using gating strategies depicted in Supplementary Fig. 1A. 
Flow cytometry was started in the seventh month of the study. Routine counts were measured with the Sysmex 
XN-1000 throughout the study.
Ex-vivo whole blood stimulation assay. Stimuli were prepared in batches at 10 times the final concen-
tration: M. tuberculosis H37Rv lysate (final concentration 5 μg/mL), Streptococcus pneumoniae lysate (106 colony 
forming units per millilitre, CFU/mL), Escherichia coli lysate (106 CFU/mL) and Candida albicans lysate (106 
CFU/mL). Live Bacillus Calmette-Guérin (BCG) was resuspended weekly from the vaccine bottle and used at 105 
CFU/mL. Blood obtained in lithium-heparin tubes (Greiner) was stored at 20–23 °C and processed within 24 h. 
Blood was diluted 1:4 with RPMI in a 24-well flat-bottom culture plate and incubated in the presence of the above 
mentioned stimuli, or left unstimulated, for 24 h after which supernatant was stored in two aliquots at −80 °C till 
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batch-wise measurement by ELISA: interleukin-1 (IL-1β), IL-1 receptor antagonist (IL-1Ra), tumour necrosis 
factor alpha (TNF-α) (all from R&D Systems, Minneapolis, MN), and IL-6, IL-10 and interferon-gamma (IFN-γ) 
(Sanquin, Amsterdam, the Netherlands).
Data analysis. Samples were excluded if they did not meet the technical minimum requirements. For flow 
cytometry, we excluded CSF samples obtained after start of dexamethasone or not resuspended in medium within 
2.5 h, and those with inadequate fluorochrome staining or inadequate microparticle count in one of four panels. 
For ex-vivo stimulation we excluded blood samples obtained after start of dexamethasone, processed more than 
24 h after acquisition, and those with TNF-α above the detection limit of 90 pg/mL for the unstimulated control. 
Analysis was first performed on the cytokine data for the key stimuli BCG, M. tuberculosis and S. pneumoniae, 
which were complete. Then, E. coli and C. albicans was included in the analysis for the patients for whom this data 
was complete.
Analyses were performed in R 3.2.2 (http://www.R-project.org). Non-parametric tests were used for all 
continuous variables. For principal component analysis (PCA), the covariance matrix was calculated on 
log-transformed, mean-centered, cytokine data for TBM patients using the R package prcomp. Only stimuli for 
which data were complete were included. Patients and controls scores were subsequently projected on the princi-
pal components (PCs) using this covariance matrix. A correlation matrix was made using Spearman correlation 
on pair-wise complete data. Survival analysis was performed using Cox regression with the R packages survival 
and visualised with survminer. Other packages used were corrplot, dplyr, openxlsx, reshape2 and tableone, and 
graphs were visualised using ggplot2 enhanced by cowplot.
Results
patients and quality control. Of 160 patients with suspected tuberculous meningitis (TBM) who were 
immunophenotyped, 47 HIV-negative patients did not meet the TBM case definition, and 29 were HIV-positive. 
After exclusion of samples because of technical issues or because sampling had been performed after the first 
dose of dexamethasone, 67 HIV-negative TBM patients could be included in the final analysis (Fig. 1). These 67 
patients, 69.0% of whom had culture-confirmed TBM, presented with severe disease, 94.4% with grade II or III. 
TBM patients were slightly younger than pulmonary tuberculosis patients and healthy controls, while sex was 
similarly distributed (Table 1). Clinical follow-up was complete for all but one TBM patient and 180-day mortality 
was 40% (Supplementary Table 1, Supplementary Fig. 1B). Cell counts as measured by flow cytometry showed 
good correlation with routine cell counts (R2 0.45–0.65 in blood, 0.53–0.70 in CSF, Supplementary Fig. 1C), 
although they were systematically lower. The ratio of cell counts using flow cytometry compared to routine counts 
Figure 1. Patient inclusion diagram. Of the 26 patients with pulmonary tuberculosis, one had no ex-vivo 
cytokine response available. Of the 27 healthy controls, one had no ex-vivo cytokine response and one had no 
flow cytometry results available. LP = lumbar puncture.
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was 0.73 for blood neutrophils, 0.76 for blood lymphocytes, 0.42 for blood monocytes, 0.19 for CSF neutrophils 
and 0.46 for CSF mononuclear cells. These values were not influenced by time from lumbar puncture to resuspen-
sion in medium or time to flow cytometric analysis (data not shown). Fifteen patients were excluded from ex-vivo 
cytokine analysis as result of a batch of contaminated lithium-heparin tubes.
TBM is characterised by a predominance of myeloid cells in blood, and αβt cells in 
CSF. Individual variation was large (Fig. 2A), but blood of TBM and pulmonary tuberculosis patients showed a 
consistently stronger myeloid response compared to healthy controls (Table 1), with increased numbers of mature 
(CD16+) neutrophils and classical (CD14++CD16−) monocytes. Intermediate (CD14++CD16+) and nonclassi-
cal (CD14+CD16++) monocytes were lower in TBM patients compared to both control groups. The lymphoid 
response showed the opposite: counts of all lymphocyte subsets were lower in TBM patients compared to both 
pulmonary tuberculosis patients and healthy controls (Fig. 2B). In patients who survived past day 10, mature 
neutrophils showed a further increase while the number of classical monocytes decreased. The CSF cell count of 
TBM patients also showed a large variation, both in total cell number (median 68/μL, IQR 34–147 as measured by 
flow cytometry) and in proportions of different cell populations (Fig. 2C). In the lymphoid compartment (median 
49/μL, IQR 25–85), αβT cells predominated (57%, IQR 43–73 of lymphocytes), with NK cells as the second 
largest group (13%, IQR 9–24), with most NK cells CD56+. γδT cells (1.5%, IQR 0.9–3.6) were predominantly 
Vδ2+, but Vδ2− cells were also present in all but one patient. Small, but well-defined populations of MAIT cells 
(0.4%, IQR 0.3–0.8) and NKT cells (0.06%, IQR 0.03–0.12) were found in all but one and three patients, respec-
tively. Monocytes only made up a small proportion (2%) of all CSF cells, but this could be an underestimation 
because of a larger loss of myeloid cells during sample preparation. Indeed, neutrophils made up 40% of CSF cells 
in the routine measurement and only 17% by flow cytometry. The large majority (95%) of neutrophils were of 
the mature (CD16+) phenotype (Fig. 2D). Although variable between individuals, all blood lymphocyte subsets 
remained diminished during follow-up, while in CSF leukocyte counts had dropped by 59% at day 10, with αβT 
cells remaining the predominant cell type (Supplementary Fig. 2).
CSF leukocytes are more activated than blood leukocytes. CD16+ neutrophils showed higher 
expression of the neutrophil activation marker CD69 in CSF compared to blood (MFI 4.3 versus 2.4, p < 0.001), 
while there was no difference for the smaller CD16low neutrophil population. CSF monocytes showed higher 
HLA-DR expression in the classical (CD14++CD16−, MFI 21.3 versus 7.7, p < 0.001) and intermediate 
TBM PTB HC comparison (p)
42 26 26
TBM vs PTB TBM vs HCCSF blood blood blood
sex N-% male 23 (55%) 12 (48%) 10 (39%) 0.660 0.290
age year 27 (20–36) 31 (24–43) 37 (24–52) 0.042 0.024
routine haematology counts
   total leukocytes ×109 cells/L 0.216 (0.136–0.430) 10.1 (8.8–12.0) 9.1 (7.6–10.7) 6.9 (5.8–7.5) 0.088 <0.001
   neutrophils ×109 cells/L 0.069 (0.026–0.162) 8.6 (7.1–10.2) 6.4 (5.2–8.2) 4.0 (3.3–4.8) <0.001 <0.001
   lymphocytes ×109 cells/L
0.138 (0.087–0.251)*
0.8 (0.4–1.2) 1.5 (1.3–1.8) 2.3 (1.8–2.6) 0.005 <0.001
   monocytes ×109 cells/L 0.7 (0.5–1.0) 0.6 (0.5–0.8) 0.4 (0.3–0.5) 0.705 <0.001
   thrombocytes ×109 platelets/L n/a 267 (229–347) 396 (345–480) 285 (240–326) <0.001 0.562
flow cytometry results
   total leukocytes ×106 cells/L 68.4 (33.6–146.9) 7217.5 (5608.5–9258.6) 6998.1 (5129.2–8629.9) 4052.1 (3757.1–5058.8) 0.276 <0.001
   CD16+ neutrophils ×106 cells/L 12.0 (2.2–47.9) 6000.8 (4254.4–8167.5) 5011.3 (3434.9–6522.6) 2026.3 (1847.6–2874.9) 0.038 <0.001
   CD16low neutrophils ×106 cells/L 0.5 (0.1–5.1) 113.5 (56.8–268.7) 140.7 (100.9–221.6) 237.7 (139.2–265.8) 0.684 0.101
   CD14++CD16− monocytes ×106 cells/L 1.3 (0.3–3.0) 300.2 (179.7–395.1) 260.9 (181.1–353.0) 124.8 (94.3–168.2) 0.408 <0.001
   CD14++CD16+ monocytes ×106 cells/L 0.2 (0.1–0.5) 7.3 (2.1–15.7) 17.9 (13.0–44.8) 11.1 (5.8–18.9) 0.001 0.118
   CD14+CD16++ monocytes ×106 cells/L 0.1 (0.0–0.3) 1.2 (0.5–1.8) 6.9 (3.5–23.2) 10.2 (2.2–18.0) <0.001 <0.001
   CD56- NK cells ×106 cells/L 0.8 (0.3–2.4) 5.8 (2.5–9.4) 8.3 (5.5–20.6) 21.8 (14.7–32.7) 0.011 <0.001
   CD56+ NK cells ×106 cells/L 2.7 (1.2–7.6) 48.9 (33.7–86.5) 169.6 (94.8–198.8) 164.2 (120.9–198.1) <0.001 <0.001
   CD56bright NK cells ×106 cells/L 0.5 (0.2–1.3) 1.8 (0.8–3.4) 4.9 (3.2–6.9) 5.4 (3.9–7.4) <0.001 <0.001
   MAIT cells ×106 cells/L 0.2 (0.1–0.8) 11.2 (7.6–30.7) 37.6 (12.2–59.4) 85.7 (37.0–134.0) 0.016 <0.001
   NKT cells ×106 cells/L 0.0 (0.0–0.1) 0.4 (0.1–0.8) 0.4 (0.1–1.1) 1.7 (1.3–3.4) 0.969 <0.001
   Vδ2− γδT cells ×106 cells/L 0.2 (0.1–0.6) 6.0 (1.9–11.1) 9.0 (6.4–16.7) 15.2 (7.5–24.8) 0.014 <0.001
   Vδ2+ γδT cells ×106 cells/L 0.4 (0.1–1.5) 6.7 (3.0–15.7) 16.7 (11.4–50.3) 29.5 (14.3–60.4) 0.002 <0.001
   αβT cells ×106 cells/L 25.9 (17.9–44.4) 315.5 (160.7–689.7) 817.6 (705.8–1001.2) 1115.4 (950.2–1255.3) <0.001 <0.001
Table 1. Comparison of tuberculous meningitis (TBM) patients versus pulmonary tuberculosis (PTB) patients 
and healthy controls (HC). Presented are the baseline characteristics of age and sex, routinely obtained cell 
counts and cell counts by flow cytometry. Comparisons are made by Mann-Whitney U for blood of TBM 
versus PTB and HC respectively. *CSF mononuclear cells. Routine CSF leukocyte analysis by Sysmex does not 
differentiate lymphocytes and monocytes, together categorized as mononuclear cells.
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(CD14++CD16+, MFI 24.4 versus 17.7, p = 0.043) subpopulations than in blood (Fig. 3A). The difference in 
activation was even more pronounced in the lymphoid component, with five-fold higher CD69 on NK cells 
in CSF compared to blood (MFI 10.4 versus 2.0, p < 0.001) and nine-fold higher CD69 on T cells (MFI 10.8 
vs. 1.2, p < 0.001, Fig. 3B). The most activated monocytes were nonclassical (CD14+CD16++) and interme-
diate (CD14++CD16+) monocytes that were overrepresented among CSF monocytes compared to blood. 
Likewise, CD56bright NK cells had the largest proportional presence in CSF compared to blood among NK cells 
(Supplementary Fig. 3A,B). During follow-up, a gradual decrease in CSF activation was seen (Supplementary 
Fig. 3C).
TBM patients show a broad range in ex-vivo cytokine responses. Overall, pulmonary tuberculosis 
patients had the highest cytokine responses but TBM patients showed the widest range in cytokine production 
(example for IL-1β in Fig. 4A, Table 2). Principal component analysis on the responses to live BCG, M. tubercu-
losis and S. pneumoniae lysate for all six cytokines resulted in a first component (PC1, representing 45% of varia-
tion) that was largely determined by IL-1β, IL-6, IL-10 and TNF-α in response to all three stimuli (Supplementary 
Fig. 4A). TBM patients showed a much more heterogeneous response compared to pulmonary tuberculosis 
patients (p = 0.002, Levene’s test for homogeneity) and healthy controls (p < 0.001), as shown in Fig. 4B. The 
ex-vivo response of TBM patients showed a gradient in the monocyte-derived cytokines TNF-α, IL-1β, IL-6 and 
IL-10 after stimulation with the specific stimuli, BCG and M. tuberculosis, but also with the non-mycobacterial 
stimulus S. pneumoniae (Fig. 4C). Data for C. albicans (not available for every patient) showed a similar gradient 
while E. coli (also incomplete) did not (data not shown).
During follow-up, cytokine responses showed a decrease from baseline to day 10 (all but two patients had 
started on corticosteroids), and an increase again at day 60 and 180 (Supplementary Fig. 4B). The response of 
Figure 2. Flow cytometry results. (A) Blood flow cytometry results for 40 tuberculous meningitis (TBM) 
patients showing concentrations of individual cell types as depicted in the legend. (B) Median concentrations 
in 26 healthy controls, 26 pulmonary tuberculosis and TBM patients for myeloid (left) and lymphoid (right) 
cell types. (C) CSF flow cytometry results for 41 individual TBM patients. Patients with >200 leukocytes/μL 
are displayed in the left subplot and patients with ≤200 leukocytes/μL in the right subplot. (D) Median CSF 
cell composition of all TBM patients combined. Note: CD3− lymphocytes without NK cell markers, most likely 
B cells (14%, IQR 11–43 of lymphocytes), were not included in the analysis because the flow cytometry panels 
lacked B-cell markers to formally confirm their phenotype.
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TBM patients at day 180 was higher than that of healthy controls for cytokines induced by multiple stimuli: 
IFN-γ and IL-1RA induced by BCG; TNF-α, IFN-γ, IL-6, IL1-RA induced by M. tuberculosis; TNF-α, IFN-γ and 
IL-1RA induced by S. pneumoniae; and IL-1RA induced by C. albicans (p < 0.05 for all, data not shown).
Immune responses correlate to clinical characteristics and survival. Contrary to our hypothesis, 
we found a broad range in immune responses in TBM patients rather than clearly distinct immune phenotypes 
(‘high’ and ‘low’ responders). We therefore looked for correlations between cell distribution, cell activation and 
ex-vivo cytokine responses. Myeloid CSF cells correlated with other myeloid cells and lymphoid CSF cells with 
other lymphoid CSF cells, and the same was true for blood cells. Little or no correlation was seen between the CSF 
and blood markers (Supplementary Fig. 5).
We next examined the link between ex-vivo cytokine responses, blood flow cytometry and clinical character-
istics. Activation of CD14++CD16− (classical) blood monocytes measured by HLA-DR showed a positive corre-
lation with the first principal component of the ex-vivo cytokine response (Spearman rho = 0.52, p = 0.0089), and 
this was largely driven by the TNF-α, IL-6 and IL-10 responses across the range of stimuli. Not unexpectedly, the 
first principal component of the ex-vivo cytokine response also correlated positively to the following routinely 
collected clinical parameters: temperature (rho = 0.33, p = 0.0183), blood lymphocytes (rho = 0.40, p = 0.0048) 
and blood monocytes (rho = 0.34, p = 0.0171).
Finally, we tested if immune markers predicted patient survival. Neither ex-vivo cytokine responses nor blood 
count markers showed an association with outcome, while higher levels of the main CSF lymphoid cell types 
(αβT and NK cells), were associated with better outcome (Table 3).
Discussion
In this prospective cohort of carefully characterised patients in Indonesia, tuberculous meningitis (TBM) patients 
showed a strong blood myeloid response compared to healthy controls and pulmonary tuberculosis patients. 
Within the group of TBM patients, CSF mostly showed a predominance of αβT cells, with highly variable propor-
tions of NK cells and neutrophils, and higher expression of activation markers on CSF monocytes, neutrophils, 
NK cells and T cells than on these same cell types in blood. Whole blood ex-vivo cytokine responses showed 
a much wider range in TBM patients compared to pulmonary tuberculosis patients and controls. Rather than 
distinct immune phenotypes, a gradual scale in the immune response was seen with high cytokine responses 
correlating with other inflammatory markers.
This study is the first to quantify innate cell population concentrations in blood and CSF of TBM patients 
in comparison to relevant control groups, adding to previous studies that reported low numbers of αβT cells 
in blood of TBM patients15 (probably due to compartmentalisation to CSF16), and the presence of γδT and NK 
cells in CSF8. In CSF, besides αβT cells the most abundant cell type were NK cells, an important source of IFN-γ 
Figure 3. Blood versus CSF leukocyte activation. Median fluorescence intensity of activation markers in blood 
(x-axis) versus CSF (y-axis) for myeloid (A) and lymphoid (B) cell types. These modified ‘bag plots’ show the 
50% median data-points and can thereby be compared to a two-dimension box plot without whiskers.
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and a critical CSF cytokine in TBM17. We also found NKT cells and MAIT cells in CSF, of which the latter have 
not been described in CSF before. Some patients showed a predominance of neutrophils in CSF, mostly mature, 
non-apoptotic neutrophils expressing CD16+ 18. Monocytes were found in low numbers in CSF, with propor-
tionally more CD16+ (macrophage-like) subsets than in blood and with high expression of the activation marker 
HLA-DR. Leukocyte activation was much higher in CSF than blood, with very little correlation between com-
partments, indicating that future studies cannot rely on blood flow cytometry or ex-vivo stimulation assays when 
aiming to characterise the cerebral immune response.
Whole blood cytokine responses showed a much wider range in TBM patients compared to the two con-
trol groups, ranging from non-responsiveness to hyper-responsiveness. This gradient in production of TNF-α, 
IL-1β, IL-6 and IL-10 was seen in response to the mycobacterial stimuli BCG and M. tuberculosis as well as to 
non-mycobacterial stimuli S. pneumonia and C. albicans. Ex-vivo cytokine responses showed a positive correlation 
with blood lymphocyte and monocyte counts and especially with HLA-DR expression on monocytes. Ex-vivo 
cytokine responses also correlated positively with body temperature, which predicted early mortality in our pre-
vious study on routine inflammatory markers in 499 HIV-negative TBM patients5. Other studies have shown that 
immunoparalytic sepsis patients with low cytokine responses have higher mortality later during the course of dis-
ease, possibly because of a higher rate of secondary infection19, but we could not confirm this in our present study.
Figure 4. Ex-vivo whole blood cytokine results. (A) IL-1β response after stimulation of whole blood with 
BCG, M. tuberculosis and S. pneumoniae for each of the three patient groups tuberculous meningitis (TBM), 
pulmonary tuberculosis (PTB) and healthy controls (HC). (B) Comparison of these patient groups on principal 
component (PC) 1 versus PC2 in principal component analysis of all six measured cytokines for the afore-
mentioned stimuli for three patient groups. (C) Heatmap showing the combination of six cytokines and three 
stimuli (y-axis; B = BCG, M = M. tuberculosis and S = S. pneumoniae) for all 50 included TBM patients (x-axis) 
sorted on their score on PC1.
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At 10 days post admission, a remarkable decrease in CSF myeloid cells and all lymphoid cells except αβT cells 
was seen. Different from a Vietnamese study analysing dexamethasone versus placebo that used comparable 
methodology8, ex-vivo cytokine responses were strongly down regulated in our patients at day 10. We consider 
this to be the effect of corticosteroid treatment because the cytokine production was restored after cessation of 
steroids after 6 weeks (day 60 and 180 measurements). At day 180, proinflammatory cytokine production were 
even higher than in healthy controls, both in response to mycobacterial stimuli as shown before20, as well as to 
unrelated stimuli C. albicans and S. pneumoniae. Our findings show similarities to HIV-associated cryptococ-
cal meningitis with proportionally overrepresented CD56bright NK cells and CD14++CD16+ and CD14+CD16++ 
monocytes in CSF compared to blood21 and a subgroup of patients with low HLA-DR on monocytes and low 
ex-vivo TNF-α22.
Our study has several limitations. Although much larger than previous studies, caution is warranted in its 
interpretation because of the many comparisons relative to the number of included individuals. Our follow-up 
was 99% complete, but high early mortality compromised follow-up sampling. Also, CSF leukocytes, especially 
myeloid cells, show an almost 40% loss from 30 to 60 minutes after lumbar puncture23. To limit cell loss, we imme-
diately resuspended CSF cells in culture medium. For the ex-vivo cytokine assay, we chose 24 hours incubation. 
Patient group (n) Comparison (p)
TBM PTB HC
TBM vs PTB TBM vs HC50 25 26
IFN-γ (pg/mL)
   BCG 18 (10–22) 21 (13–26) 16 (11–29) 0.317 0.742
   M. tuberculosis 16 (12–24) 16 (12–31) 14 (8–24) 0.482 0.517
   S. pneumoniae 23 (16–35) 33 (16–47) 24 (15–35) 0.070 0.622
   E. coli 15 (10–19) 14 (12–18) 16 (10–26) 0.843 0.381
   C. albicans 12 (9–21) 24 (17–29) 20 (15–32) 0.004 0.008
TNF-α (pg/mL)
   BCG 334 (142–847) 930 (538–1530) 252 (128–356) 0.004 0.119
   M. tuberculosis 359 (97–803) 466 (215–1036) 83 (50–157) 0.214 0.001
   S. pneumoniae 591 (136–1029) 1387 (1125–1668) 369 (202–647) <0.001 0.405
   E. coli 365 (104–1242) 915 (333–1569) 391 (206–773) 0.033 0.889
   C. albicans 122 (52–426) 139 (70–259) 153 (100–217) 0.872 0.901
IL-1β (pg/mL)
   BCG 167 (79–393) 363 (204–761) 183 (106–382) 0.012 0.653
   M. tuberculosis 200 (53–449) 335 (186–619) 178 (129–260) 0.055 0.921
   S. pneumoniae 474 (134–968) 1477 (1055–1749) 721 (366–935) <0.001 0.124
   E. coli 288 (42–473) 760 (486–1037) 667 (195–944) <0.001 0.005
   C. albicans 95 (37–193) 106 (53–131) 104 (66–161) 0.713 0.499
IL-6 (pg/mL)
   BCG 2838 (1056–5108) 6052 (4477–9882) 2888 (1731–4750) 0.001 0.878
   M. tuberculosis 2281 (700–6104) 4000 (2986–7269) 1574 (850–2728) 0.027 0.191
   S. pneumoniae 1635 (573–3114) 2183 (1667–3047) 1530 (971–2160) 0.071 0.965
   E. coli 2068 (607–3284) 3331 (2379–5149) 2179 (1363–3024) 0.009 0.901
   C. albicans 1151 (411–2436) 1192 (486–1630) 694 (318–1101) 0.648 0.107
IL-10 (pg/mL)
   BCG 39 (12–81) 52 (44–84) 35 (24–53) 0.132 0.801
   M. tuberculosis 21 (10–59) 36 (17–44) 14 (6–25) 0.386 0.077
   S. pneumoniae 33 (15–54) 38 (21–55) 24 (13–40) 0.458 0.187
   E. coli 38 (5–67) 51 (32–89) 61 (28–73) 0.106 0.258
   C. albicans 6 (5–32) 5 (5–13) 6 (5–9) 0.457 0.383
IL-1RA (pg/mL)
   BCG 3810 (2020–6132) 4833 (3210–6209) 1597 (1290–2269) 0.160 <0.001
   M. tuberculosis 3366 (1924–6719) 4651 (2677–5980) 1645 (1325–2067) 0.351 <0.001
   S. pneumoniae 3948 (1826–5861) 6083 (4499–10546) 1728 (956–2270) 0.002 <0.001
   E. coli 3902 (1647–6512) 6901 (3789–8459) 2830 (2329–3739) 0.006 0.143
   C. albicans 1633 (1132–3071) 2334 (1751–3361) 908 (604–1578) 0.146 0.002
Table 2. Whole blood ex-vivo cytokine results at baseline for tuberculous meningitis (TBM) versus pulmonary 
tuberculosis (PTB) and healthy controls (HC). Mann-Whitney U p-values for are shown. Data were missing for 
one pulmonary tuberculosis patient and one healthy control. Data are 100% complete for BCG, M. tuberculosis 
and S. pneumoniae, 87% for E. coli and 76% for C. albicans.
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This is optimal for measuring for monocyte-derived cytokines24, but relatively short for IFN-γ. Cytokines in CSF 
were not measured in this study. The correlations of the ex-vivo cytokine response, require validation in a separate 
cohort given their number.
What is the clinical relevance of our findings? Besides better supportive care25 and higher dose rifampicin26, 
immunomodulatory therapy may be a third strategy to improve treatment of TBM. In the sepsis field a 
one-size-fits-all approach has not been successful27. Our findings suggest that the same may be true for TBM. 
There could be a role additional anti-inflammatory therapy, i.e. with aspirin4,28, or interleukin-1 receptor antag-
onist for patients with a strong inflammatory response. At the same time, patients with a low response might 
have a better outcome without corticosteroid treatment, or might even benefit from adjuvant IFN-γ therapy to 
boost their immune response, as has been done successfully in a child with protracted TBM29. Preferably, future 
host-directed trials should include immune markers to allow for post-hoc identification of subgroups benefitting 
from the initiated therapy. Good candidates are blood monocyte HLD-DR expression, well generalizable to other 
settings, and ex-vivo cytokine responses. Because of the lack of correlation between blood and CSF compart-
ments, we recommend to also include CSF markers when studying adjuvant therapies.
In conclusion, TBM patients show a previously not appreciated strong myeloid blood response, a remarkably 
broad lymphoid CSF response including innate lymphocytes, and an unexpectedly large gradient in the immune 
response, with little correlation between blood and CSF compartments. We recommend integrating the assess-
ment of the immune response in future randomised clinical trials evaluating host-directed therapy in TBM.
Data Availability
The datasets generated in the current study are available from the corresponding author on reasonable request.
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